论文信息 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up - 字舞流文

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

P. Sonneveld | L. Pacaud | E. Zudaire | T. Kerre | P. Mistry | S. Zweegman | N. V. D. van de Donk | A. Cohen | Y. Cohen | Jordan M. Schecter | S. Anguille | Carolyn C. Jackson | K. D. De Braganca | H. Varsos | M. Akram | D. Geng | W. Roeloffzen | M. Agha | T. Roccia | N. W. van de Donk | Xiaoying Xu | C. Corsale | Katherine Li | Jordan Schecter